New data show aficamten improves heart structure and symptoms in hypertrophic cardiomyopathy patients

Cytokinetics presented new clinical data on aficamten at the 2026 HCMS Scientific Sessions, showing it improves cardiac structure and patient symptoms in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). The ACACIA-HCM trial demonstrated significant reductions in heart muscle thickness and biomarkers of cardiac stress in non-obstructive HCM patients. Patient-reported health status also improved, with benefits sustained during treatment but reversing after withdrawal. Long-term data from FOREST-HCM confirmed aficamten's safety and tolerability in obstructive HCM. Cytokinetics plans to submit a supplemental drug application for non-obstructive HCM treatment in late 2026.

Cytokinetics Inc (CYTK) shares rose 2.16% to USD 54.85 as of Nov 09, 2026 19:41 WIB on Pluang. The stock trades near its 52-week low of USD 53.69, well below the high of USD 87.26. Market participants hold CYTK for an average of 21 days, reflecting active interest in this health sector stock amid ongoing clinical developments.